HZO
MarineMax, Inc.
HZO has a slight edge over LCID overall, supported by lower modeled downside.
LCID
Lucid Group, Inc.
LCID offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
HZO Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Stable | |
| Healthy | |
| Weak |
HZO's cash flow is currently healthy, and its profitability is stable, but its revenue and balance sheet are under pressure.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
HZO PE Valuation
HZO has no meaningful PE right now: it lost money over the past year.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
HZO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Stable | |
| Improving | |
| Limited | |
| Low |
Analysts expect HZO's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
HZO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.61 | — |
| Q3 2026 | -$0.41 | +$1.02 |
HZO has the edge over LCID in the latest year-over-year earnings comparison.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
HZO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $520.1M | -5.8% |
| Q2 2026 | $611.3M | -7% |
| Q1 2026 | $527.4M | -16% |
| Q4 2025 | $505.2M | +7.8% |
HZO's revenue has slid since its 2025 peak: $520M last quarter, down 5.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 6.1% | +12 points |
| Q1 2026 | 2% | -1.6 points |
| Q4 2025 | 1% | -7.4 points |
| Q3 2025 | 2.5% | N/A |
| Q2 2025 | -6.3% | N/A |
| Q1 2025 | 3.6% | N/A |
| Q4 2024 | 8.3% | N/A |
HZO has the edge over LCID on profitability, with a higher operating margin.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over HZO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
HZO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $77.2M | +13% |
| Q1 2026 | $44.5M | -26% |
| Q4 2025 | $8.3M | +$172.7M |
HZO and LCID do not have enough comparable growth data to identify a winner.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
HZO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5.1% | +1.1M shares |
| 1 year | +7.6% | +1.6M shares |
HZO has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2025 | — |
| Q2 2025 | $15M |
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
HZO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 6.8x | High |
| Q1 2026 | 22.5x | High |
| Q4 2025 | 18.3x | High |
| Q3 2025 | 11.3x | High |
| Q2 2025 | 10.4x | High |
| Q1 2025 | 5.1x | High |
| Q4 2024 | 5.3x | High |
HZO's net debt is about 6.8 years of its operating earnings (EBITDA), down from 10 years a year ago.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HZO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 78.2 | Overbought |
| Stochastic | 96.4 | Overbought |
HZO's weekly RSI is 78 (overbought) and its Stochastic is 96 (overbought).
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
HZO PE vs Consumer Cyclical Sector
| Metric | HZO | Sector median | Relative |
|---|---|---|---|
| PE | 203x | 18x | 1,026% above |
| PE % | 100 | 47 | 53 pts above |
HZO has no meaningful PE right now: it lost money over the past year.
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
HZO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.6 | 0.5% above |
| 20 week MA | $47.2 | 12% above |
| 50 week MA | $36.4 | 45% above |
| 100 week MA | $30.6 | 72% above |
| 200 week MA | $31.1 | 70% above |
HZO has the edge over LCID on trend strength, trading above more of its moving averages.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
HZO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $16.7 | $37.8 | +127% |
| 2021 | $37.8 | $56.3 | +49% |
| 2022 | $56.3 | $31.0 | -45% |
| 2023 | $31.0 | $38.9 | +26% |
| 2024 | $38.9 | $27.8 | -29% |
| 2025 | $27.8 | $24.5 | -12% |
| 2026 YTD | $24.5 | $52.8 | +116% |
HZO has the edge over LCID on returns for 2026, with the stronger performance.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.